The use of doravirme as part of antiretroviral therapy regimens in patients with resistance mutations


Cite item

Full Text

Open Access Open Access
Restricted Access Access granted
Restricted Access Subscription or Fee Access

Abstract

The paper deals with a clinical experience in following up 12 HIV-infected patients with a history of multiple switches to ART regimens and with resistance mutations, who have been switched to an ART DOR/3TC/TDF + DTG regimen in routine clinical practice. The available HIV-1 RNA data show that at one month after switching to a new regimen, 8 of the 12 patients and at 6 month, 8 of the 9 patients achieved an undetectable viral load. Further patient follow-up is needed.

Full Text

Restricted Access

About the authors

Elena A. Orlova-Morozova

Moscow Regional Center for Prevention and Control of AIDS and Communicable Diseases

Email: orlovamorozova@gmail.com
Cand. Med. Sci., Head, Outpatient Department

Alexander Yu. Pronin

Moscow Regional Center for Prevention and Control of AIDS and Communicable Diseases

Email: alexanderp909@gmail.com
Cand. Med. Sci., Head

References

  1. Всемирная организация здравоохранения. Глобальная стратегия сектора здравоохранения по ликвидации ВИЧ на 2016-2021. 2016. https://apps.who.int/iris/bitstream/handle/10665/255763/WHO-HIV-2016.05-rus.pdf;jsessionid=09 DCDD724175F1C737E6A1797499F575?sequence=1
  2. Государственная стратегия противодействия распространению ВИЧ- инфекции в Российской Федерации на период до 2020 года и дальнейшую перспективу. Утверждена Распоряжением Правительства РФ от 20.10.2016 № 2203-р. http://government.ru/docs/24983/
  3. Уровень и структура лекарственной устойчивости ВИЧ среди наивных пациентов в Российской Федерации. Анализ Российской базы данных лекарственной устойчивости ВИЧ. www.hivresist.ru
  4. База данных лекарственной устойчивости ВИЧ Стэнфордского университета. https://hivdb.stanford.edu/dr-summary/resistance-notes/NRTI/#16Larder1995
  5. Cot6 B., Burch J.D., Asante-Appiah E., Bayly Ch., B6dard L, Blouin M. еt al. Discovery of MK-1439, an orally bioavailable non-nucleoside reverse ranscriptase inhibitor potent against a wide range of resistant mutant HIV viruses. Bioorg. Med. Chem. Lett. 2014; 24(3): 917-922. doi: 10.1016/j.bmcl.2013.12.070
  6. Feng M., Sachs N.A., Xu M., Grobler J., Blair W., Hazuda D.J. et al. Doravirine suppresses common nonnucleoside reverse transcriptase inhibitor-associated mutants at clinically relevant concentrations. Antimicrob Agents Chemother. 2016; 60(4): 22412247. doi: 10.1128/AAC.02650-15
  7. Orkin C., Molina J.-M., Lombaard J., DeJesus E., Rodgers A., Kumar S. et al. Once-daily Doravirine in Human Immunodeficiency Virus Type 1-Infected, Antiretroviral-naive Adults: An Integrated Efficacy Analysis. Clin. Infect. Dis. 2020; 70(7): 1344-1352. doi: 10.1093/cid/ciz424
  8. Johnson M., Kumar P., Molina J.-M., Rizzardini G., Cahn P., Bickel M. et al. for the DRIVE-SHIFT Study Group. Switching to Doravirine/Lamivudine/ Tenofovir Disoproxil Fumarate (DOR/3TC/TDF) Maintains HIV-1 Virologic Suppression Through 48 Weeks: Results of the DRIVE-SHIFT Trial. J. Acquir. Immune Defic. Syndr. 2019; 81(4): 463 -472. doi: 10.1097/ QAI.0000000000002056
  9. Wong A., Goldstein D., Mallolas J., DeJesus E., Johnson M., J.-M. Molina J.-M. et al. Efficacy and Safety of Doravirine/ Lamivudine/Tenofovir Disoproxil Fumarate (DOR/3TC/ TDF) in Treatment-Naive Adults With HIV-1 and Transmitted Nonnucleoside Reverse Transcriptase Inhibitor Resistance Mutations. J. Acquir. Immune Defic. Syndr. 2019; 82(4): e47-e49. doi: 10.1097/QAI.0000000000002153
  10. Soulie C., Santoro M.M., Charpentier C., Storto A., Paraskevis D., Di Carlo D. et al. Rare occurrence of doravirine resistance-associated mutations in HIV-1-infected treatment-naive patients. J. Antimicrob. Chemother. 2019; 74(3): 614-617. doi: 10.1093/jac/ dky464

Supplementary files

Supplementary Files
Action
1. JATS XML

Copyright (c) 2021 Bionika Media

This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies